The first patient was dosed with our investigationalIn a research or clinical setting, investigational means that the drug has not been approved or authorized for use in patients outside of a clinical trial by any authority that regulates new treatments, such as the U.S. Food and Drug Administration (FDA) or United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA). genome editingAlso called gene editing. Genome editing collectively refers to a set of technologies, including CRISPR/Cas9, that can be used to cut and modify DNA. Genome editing uses systems to make the DNA change inside the cell. These cells can be edited in the body (in vivo) or outside the body (ex vivo) from a patient or donor. treatment for transthyretin amyloidosisAlso known as ATTR. A rare genetic disease caused by accumulation of misfolded transthyretin (TTR) protein, which affects the nerves, heart, kidneys and eyes. Patients can develop amyloidosis by inheriting the faulty TTR gene from a parent (hereditary or hATTR) or due to a natural form of this protein, without genetic mutation (wild-type or wtATTR). NTLA-2001, Intellia’s first investigational therapy, is being evaluated in a Phase 1 clinical trial as a treatment for people who have hereditary ATTR with polyneuropathy. (ATTRAlso known as ATTR. A rare genetic disease caused by accumulation of misfolded transthyretin (TTR) protein, which affects the nerves, heart, kidneys and eyes. Patients can develop amyloidosis by inheriting the faulty TTR gene from a parent (hereditary or hATTR) or due to a natural form of this protein, without genetic mutation (wild-type or wtATTR). NTLA-2001, Intellia’s first investigational therapy, is being evaluated in a Phase 1 clinical trial as a treatment for people who have hereditary ATTR with polyneuropathy.) in November 2020.
Our modular approach enables us to optimize the power and versatility of the CRISPR/Cas9Adapted from a naturally occurring bacterial immune system, CRISPR is an acronym for Clustered Regularly Interspaced Short Palindromic Repeats. One of the proteins in the CRISPR system is known as CRISPR-associated 9 protein or Cas9 protein, which acts as a pair of ‘molecular scissors’ to cleave DNA. Researchers have co-opted the bacterial CRISPR/Cas9 system to make specific changes in the DNA of humans, other animals and plants. CRISPR/Cas9 was first harnessed in 2012 as a genome editing tool in the lab. More recently, scientists have begun engineering and testing CRISPR systems to be very specific to a desired genetic target. technology and, importantly, allows us to rapidly develop therapeutics for numerous diseases that currently have limited treatment options.
ATTR Program:
- NTLA-2001 could be the first curative treatment for transthyretin amyloidosisAlso known as ATTR. A rare genetic disease caused by accumulation of misfolded transthyretin (TTR) protein, which affects the nerves, heart, kidneys and eyes. Patients can develop amyloidosis by inheriting the faulty TTR gene from a parent (hereditary or hATTR) or due to a natural form of this protein, without genetic mutation (wild-type or wtATTR). NTLA-2001, Intellia’s first investigational therapy, is being evaluated in a Phase 1 clinical trial as a treatment for people who have hereditary ATTR with polyneuropathy. (ATTR). By applying the company’s in vivoMeaning “within the living”, this type of therapy is administered directly into the patient, targeting the cells and editing the genome from inside the body. liver knockout approach, NTLA-2001 has the potential for lifelong reduction of TTR protein and reversing disease progression with a single course of treatment. The investigational therapy is delivered with Intellia’s proprietary non-viral lipid nanoparticle platform, which the company is using to develop other in vivo treatments. Our goal is to address all forms of ATTR, regardless of disease type, with a single course of treatment.
- ATTR is a progressive and fatal disease that results from the build-up of a misfolded form of the TTR proteinAlso known as TTR protein. Produced by the TTR gene. The disease, ATTR, occurs when a specific DNA mutation occurs in the TTR gene that causes the liver to produce the TTR protein in a misfolded form. This misfolded protein can build up in the body and lead to disease-causing nerve and other organ damage., leading to diverse disease manifestations and disease progression, including peripheral neuropathy and cardiomyopathyATTR resulting in heart muscle disease, and manifested through symptoms that include shortness of breath, palpitations and abnormal heart rhythm, ankle swelling (edema), fainting, fatigue and chest pain (angina). Can also lead to heart failure. Intellia is currently investigating NTLA-2001 as a treatment for people who have hereditary ATTR with polyneuropathy. In the future, Intellia's goal is to address hereditary and wild-type ATTR, both polyneuropathy and cardiomyopathy, with a single course of treatment..
- NTLA-2001 is the first systemically delivered investigational CRISPR/Cas9 therapy to enter the clinic. Intellia dosed the first patient in the company’s global Phase 1 clinical trialA test of a new medical treatment or procedure in human volunteers with the purpose of evaluating a medical, surgical or behavioral intervention. Clinical trials typically follow preclinical (non-human) studies and are the primary way that clinical researchers and regulatory agencies evaluate whether a new treatment is safe and effective in people. in November 2020, evaluating NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathyATTR resulting in severe and permanent peripheral nerve damage, and manifested through symptoms that include tingling and numbness in legs and feet, difficulty walking, limb weakness and pain. Polyneuropathy is also known as peripheral neuropathy. Intellia’s first therapeutic candidate, NTLA-2001, is being studied in the clinic as a single-course treatment for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN). (hATTR-PN). Once safety and an optimal dose have been determined, Intellia intends to further evaluate NTLA-2001 in a broader ATTR patient population. Beyond receiving authorization in the U.K. to initiate this trial, Intellia is submitting additional regulatory applications in other countries as part of its global clinical development plans.
- In support of NTLA-2001, Intellia completed a 12-month preclinical durability study of its lead lipid nanoparticleAlso known as LNP. LNPs are fat-based molecules that are the basis of Intellia’s CRISPR/Cas9 delivery platform. In Intellia’s experimental treatments, an LNP delivers to its target gene a simple, two-part genome editing system: the messenger RNA that encodes the Cas9 protein and the guide RNA that can target a specific DNA sequence. (LNP) formulation, which showed maintenance of an average reduction of >95% of serum TTR proteinAlso known as TTR protein. Produced by the TTR gene. The disease, ATTR, occurs when a specific DNA mutation occurs in the TTR gene that causes the liver to produce the TTR protein in a misfolded form. This misfolded protein can build up in the body and lead to disease-causing nerve and other organ damage. and sustained liver editing after a single dose in non-human primates.
- We lead the development of NTLA-2001, which we are co-developing with Regeneron.
HAE Program:
- NTLA-2002 is Intellia’s development candidate for the treatment of hereditary angioedemaAlso known as HAE. Rare and potentially life-threatening genetic disease characterized by overproduction of bradykinin, which leads to recurring, severe and unpredictable swelling in various parts of the body. (HAE) and is our second in vivo knockoutInactivation/deletion of a DNA sequence using a gene editing technology, such as the CRISPR/Cas9 system. This is the type of gene edit employed by NTLA-2001. therapeutic candidate. We expect to submit an INDAlso known as an IND or IND application. Companies like Intellia submit an IND to begin testing of investigational therapies in humans in the U.S. An IND is equivalent to a CTA, the regulatory application required in many countries outside the U.S. to begin clinical testing. or IND-equivalent in 2H 2021.
- HAE is a rare genetic disorder characterized by recurring and unpredictable severe swelling attacks in various parts of the body, and is significantly debilitating and disabling. The disease is caused by increased levels of bradykinin, a protein which leads to swelling. NTLA-2002 aims to prevent unregulated production of bradykinin by knocking out the prekallikrein B1 (KLKB1Also known as KLKB1 gene. Knocking out this gene is expected to reduce kallikrein activity, which is involved in the biological pathway for release of bradykinin. Intellia expects this reduction to correlate with a decrease in bradykinin activity, thus, preventing the activation of endothelial cells that causes vascular leakage and angioedema in HAE patients.) gene through a single course of treatment to ameliorate the frequency and intensity of these swelling attacks.
- Intellia’s KLKB1 HAE program is subject to an option by Regeneron to enter into a co-development/co-promotion agreement, in which Intellia would remain the lead party.
Hemophilia A and BSevere, rare genetic bleeding disorders, each caused by a different missing or defective clotting protein. Programs:
- In June 2020, Intellia and Regeneron expanded and extended their collaboration to research and develop CRISPR/Cas9-based treatments. Under the terms of two co-development and co-commercialization agreements, Intellia and Regeneron agreed to co-develop potential hemophilia A and BSevere, rare genetic bleeding disorders, each caused by a different missing or defective clotting protein. CRISPR/Cas9-based treatments using their jointly owned targeted transgeneA gene introduced into the genome by artificial (e.g. not found in nature) means. To perform targeted gene insertion, a transgene must be delivered to the cell nucleus and once there, fulfill the intended role of the gene, such as restoring protein production or recognizing an immune antigen. insertionInsertion of a new DNA sequence into the genome to manufacture a desired protein using a gene editing technology, such as the CRISPR/Cas9 system. technology. Regeneron is the lead party for both hemophilia A and hemophilia BSevere, rare genetic bleeding disorders, each caused by a different missing or defective clotting protein. development programs.
- These programs build on proprietary innovations developed by Intellia in its collaboration with Regeneron. Data presented in 2019 by Intellia highlighted the promise of Intellia’s technology by demonstrating the first CRISPR-mediated, targeted transgene insertion in the liver of non-human primates, which generated circulating human Factor IX, or FIX, protein at or above normal levels necessary to treat hemophilia BSevere, rare genetic bleeding disorders, each caused by a different missing or defective clotting protein., a severe genetic bleeding disorder. View Press Release
To keep up with our progress, check out our pipeline.